Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Get Rating) – Alliance Global Partners issued their FY2022 earnings estimates for Curaleaf in a research report issued on Tuesday, November 8th. Alliance Global Partners analyst A. Grey forecasts that the company will post earnings of ($0.15) per share for the year. The consensus estimate for Curaleaf’s current full-year earnings is ($0.19) per share. Alliance Global Partners also issued estimates for Curaleaf’s Q4 2022 earnings at ($0.01) EPS, Q1 2023 earnings at ($0.01) EPS, Q2 2023 earnings at ($0.01) EPS, Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at ($0.02) EPS, FY2023 earnings at ($0.06) EPS and FY2024 earnings at ($0.07) EPS.
A number of other analysts have also recently issued reports on the stock. Seaport Res Ptn reiterated a “buy” rating on shares of Curaleaf in a research note on Monday, October 31st. Stifel Nicolaus reduced their target price on shares of Curaleaf from C$9.50 to C$8.50 in a research note on Tuesday, November 8th. BTIG Research reissued a “buy” rating on shares of Curaleaf in a research report on Friday, October 28th. Canaccord Genuity Group dropped their price target on shares of Curaleaf from C$14.50 to C$13.50 in a research report on Tuesday, August 9th. Finally, Cantor Fitzgerald dropped their price target on shares of Curaleaf from $13.50 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Curaleaf has an average rating of “Moderate Buy” and a consensus target price of $12.25.
Curaleaf Price Performance
Curaleaf Company Profile
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back-office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements.
- Get a free copy of the StockNews.com research report on Curaleaf (CURLF)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.